The current mismatch between supply and demand of organs has prompted transplant clinicians to consider innovative solutions to broaden the donor pool.
| INTRODUC TI ON
The current mismatch between supply of and demand for donor organs has prompted transplant clinicians to consider innovative solutions to broaden the donor pool. Despite a 10% increase in the number of organ donors available from 2015 to 2016, wait times remain unacceptable for the 4000 patients listed for heart transplantation in the United States. 1 Many hearts that would otherwise be acceptable go unused because the donors have hepatitis cipients. In this report, we describe the evolution of HCV treatment, ethics and informed consent, cost-effectiveness of HCV medications in treating acute HCV post-transplantation, and the Stanford experience with two HCV-viremic donor heart transplantations. We describe excellent short-term outcomes post-heart transplantation with HCV NAT-positive organs. The availability of this therapy may expand the donor pool. While we await larger-scale clinical data on the effectiveness and safety of DAA therapy in patients after heart transplantation, many transplant centers have already started accepting organs from HCV-infected donors, balancing the unknown long-term risks versus the benefits of shorter wait times and expansion of the donor pool. Protocols and multidisciplinary teams are needed to effectively communicate risk to potential recipients, to ensure timely DAA access, and to implement appropriate clinical follow-up in order to achieve excellent clinical outcomes and to maximize the donor pool by utilizing HCV-infected organs for heart transplantation. 
| D ISCUSS I ON
These 2 patients had excellent short-term outcomes after heart transplantation using organs from HCV Ab/NAT-positive donors, with neither patient experiencing any adverse drug-related side effects or clinical sequelae of HCV viremia.
Hepatitis C virus is a small, single-stranded RNA flavivirus with 6 major genotypes. In the pre-DAA era, antiviral therapy relied on 
| E THI C S AND INFORMED CON S ENT PRO CE SS
Recipient informed consent of accepting a HCV-infected organ can be a complicated process. Patients with end-stage heart failure have a chronic disease and transmission of HCV (albeit now a curable disease) as a result of transplantation can be an unwanted stressor, F I G U R E 1 Hepatitis C viral load post-heart transplant in 2 patients post-direct-acting antiviral therapy (DAA) despite the potentially shorter waiting time. Acceptance of a HCVinfected organ necessitates a multistep consent process that not only includes patient education, but also clearly communicates the unknown long-term risks of intentional transmission of HCV, along with the possible adverse consequences related to DAA therapy. 3 Clinicians must determine the optimal timing of therapy (eg, as inpatients or outpatients), monitor for drug interactions (particularly with calcineurin inhibitors), and must follow patients closely to ensure sustained virologic response is achieved (SVR, defined as an undetectable viral load). The treatment team must also anticipate issues related to insurance coverage and should proactively take measures to ensure that DAA therapy is readily available when needed. Patients should be closely followed by a multidisciplinary team, including heart transplant, immunocompromised infectious disease, and hepatology specialists for appropriate monitoring during and after DAA therapy.
| COS T-EFFEC TIVENE SS OF H C V MEDIC ATIONS
Traditionally, the incremental cost-effectiveness ratio to quality of life years threshold when considering therapies as cost-effective is $50 000, while those between $50 000 and 100 000 are considered acceptable. Currently, the cost of DAA therapy is estimated at US$80 000-100 000 for a 12-week course of therapy. Remaining on the heart transplant waiting list is also costly.
Patients who require durable mechanical cardiac support with a LVAD, for example, incur on average US$726 000 for the initial hospitalization and device implantation in addition to an annual cost of US$30 000-580 000 relating to complications and periodic visits. 2, 5 It may therefore be reasonable for insurers to cover DAA treatment after transplantation given their proven efficacy, and the high cost associated with remaining on the heart transplant waiting list.
| HOW MANY ADDITIONAL ORG ANS WILL B E AVAIL AB LE?
Since 2000, mortality associated with opioid drug overdose has increased by greater than 200% in certain regions of the United
States, where a quarter of potential donors dying of drug overdose are HCV-infected. 3 It is unclear how many of these potential donor organs were discarded due to HCV. Importantly, these donors tend to be younger, with fewer comorbidities, compared to the general organ donor population. National data suggest that acceptance of HCV-infected donors may result in an additional 300-500 solid organ transplants annually in the United States. 
| CON CLUS IONS
While we await larger-scale data on the efficacy and safety of DAA therapy in patients after heart transplantation, standardized clinical protocols and multidisciplinary teams are needed to effectively communicate risk to potential recipients, to ensure timely DAA access, and to implement appropriate clinical follow-up in order to achieve excellent post-transplant outcomes.
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